Conversely, combining anti-PD1/PDL1 with TKI therapy had a manageable safety profile and encouraging antitumor activity in other cancers, such as avelumab plus axitinib for advanced renal cell carcinoma and regorafenib plus nivolumab for advanced gastric or colorectal cancer (Motzer et al., 2019; Fukuoka et al., 2020). The gene discussed is CD274; the disease is hereditary clear cell renal cell carcinoma.